celastrol has been researched along with Sclerosis, Systemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed Abdi, B; Arora, R; Biernaskie, J; Carter, DE; Chitturi, P; Leask, A; Nguyen, J; Sinha, S; Stratton, RJ; Xu, S | 1 |
| Chen, DY; Chiu, TM; Chuang, PH; Hsu, TC; Kuo, CW; Lin, JW; Liu, CM; Tzang, BS; Tzang, CC | 1 |
| Chen, S; He, J; Jiang, X; Liu, M; Lu, W; Ye, X; Yi, C; Zhang, Q | 1 |
3 other study(ies) available for celastrol and Sclerosis, Systemic
| Article | Year |
|---|---|
Topics: Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Humans; Mice; Scleroderma, Systemic; Skin; Skin Diseases; Transcription Factors; Tripterygium | 2023 |
Effect of the Functional VP1 Unique Region of Human Parvovirus B19 in Causing Skin Fibrosis of Systemic Sclerosis.
Topics: Animals; Capsid Proteins; Fibrosis; Humans; Interleukin-6; Matrix Metalloproteinase 9; Mice; Parvoviridae Infections; Parvovirus B19, Human; Scleroderma, Systemic; Tumor Necrosis Factor-alpha; Viral Proteins | 2023 |
Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrestin; Bleomycin; Calcium; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrosis; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Pentacyclic Triterpenes; RAW 264.7 Cells; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Triterpenes | 2020 |